Michael Hayden to leave Teva as company restructures

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) announced that three executives, including President of Global R&D and CSO Michael Hayden, will leave the company, effective Dec. 31. The departures are a

Read the full 310 word article

User Sign In